Security key
98937L105
Zenas BioPharma, Inc. - Common Stock, par value $0.0001 per share (ZBIO)
CUSIP: 98937L105
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 54,499,375
- Total 13F value
- $1,065,366,720
- Share change
- +12,530,843
- Put/Call ratio
- 77%
- SEC-reported price per share
- $19.55
- Number of holders
- 137
- Value change
- +$196,744,384
- Number of buys
- 98
- Number of sells
- 45
- Shares outstanding
- 66,232,735
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
137
Top holders
10
ZBIO full security history
Ownership snapshot
Full 13F holder table
Zenas BioPharma, Inc. SEC filings
Zenas BioPharma, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of ZBIO - Zenas BioPharma, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Mar 2026
13F
13D/G
3/4/5
Lead comparable stake: 14%
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 14%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
14%
InnoCare Pharma Inc.
9.4%
Longitude Capital Partners IV, LLC
4.9%
Novo Holdings A/S
4.7%
Fairmount Healthcare Fund II L.P.
3.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
Company
|
14%
from 13D/G
|
$279,741,500
7,704,255 shares
|
— | 31 Dec 2025 |
| InnoCare Pharma Inc. |
3/4/5
13D/G
10%+ Owner
|
9.4%
from 13D/G
|
$111,026,500
5,000,000 shares
|
— | 07 Oct 2025 |
| Longitude Capital Partners IV, LLC |
13D/G
Patrick G. Enright
|
4.9%
|
$58,425,578
2,631,522 shares
|
$0 | 09 Oct 2025 |
| Novo Holdings A/S |
13F
13D/G
Company
|
4.7%
from 13D/G
|
$52,649,500
1,450,000 shares
|
— | 31 Dec 2025 |
| Fairmount Healthcare Fund II L.P. |
3/4/5
Director
|
3.6%
|
$47,180,500
2,359,025 shares
|
+$3,000,000 | 31 Mar 2026 |
| Peter Evan Harwin |
3/4/5
Director
|
3.6%
|
$47,180,500
2,359,025 shares
|
+$3,000,000 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
137
Shares
54,499,375
Rows available
137
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
137
Q1 2026 holders
137
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|